The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Potent antibody therapeutics by design
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries
Jostock, T., Vanhove, M., Brepoels, E., van Gool, R., Daukandt, M., Wehnert, A., van Hegelsom, R., Dransfield, D., Sexton, D., Devlin, M., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.03.014 · Cited by 2,572
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Self-citationCartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H.-S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,612
Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., & Winter, G. (1991) · Journal of Molecular Biology · doi:10.1016/0022-2836(91)90498-u · Cited by 1,603
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Arming antibodies: prospects and challenges for immunoconjugates
Wu, A. M., & Senter, P. D. (2005) · Nature Biotechnology · doi:10.1038/nbt1141 · Cited by 1,052
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.21.6851 · Cited by 1,039
Ward, E. S., Güssow, D., Griffiths, A. D., Jones, P. T., & Winter, G. (1989) · Nature · doi:10.1038/341544a0 · Cited by 1,003
Selecting and screening recombinant antibody libraries
Hoogenboom, H. R. (2005) · Nature Biotechnology · doi:10.1038/nbt1126 · Cited by 973
Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design
Saphire, E. O., Parren, P. W. H. I., Pantophlet, R., Zwick, M. B., Morris, G. M., Rudd, P. M., Dwek, R. A., Stanfield, R. L., Burton, D. R., & Wilson, I. A. (2001) · Science · doi:10.1126/science.1061692 · Cited by 942
Antibody Pharmacokinetics and Pharmacodynamics
Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Self-citationEngineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803
Lung biology in health and disease
Horsmanheimo, M., & Fudenberg, H. H. (1977) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(77)90040-x · Cited by 796
Koene, H. R., Kleijer, M., Algra, J., Roos, D., E.G.Kr. von dem Borne, A., & de Haas, M. (1997) · Blood · doi:10.1182/blood.v90.3.1109 · Cited by 794
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Monoclonal antibody successes in the clinic
Reichert, J. M., Rosensweig, C. J., Faden, L. B., & Dewitz, M. C. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1073 · Cited by 733
Additivity of mutational effects in proteins
Wells, J. A. (1990) · Biochemistry · doi:10.1021/bi00489a001 · Cited by 646
Perelson, A. S., & Oster, G. F. (1979) · Journal of Theoretical Biology · doi:10.1016/0022-5193(79)90275-3 · Cited by 639
Teeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
Immunogenicity of engineered antibodies
Hwang, W. Y. K., & Foote, J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.001 · Cited by 630
Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 629
Immunotherapy: past, present and future
Waldmann, T. A. (2003) · Nature Medicine · doi:10.1038/nm0303-269 · Cited by 628
Schreiber, S., Rutgeerts, P., Fedorak, R. N., Khaliq–Kareemi, M., Kamm, M. A., Boivin, M., Bernstein, C. N., Staun, M., Thomsen, O. Ø., & Innes, A. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.064 · Cited by 580
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., & Golay, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1581 · Cited by 576
The binding site for C1q on IgG
Duncan, A. R., & Winter, G. (1988) · Nature · doi:10.1038/332738a0 · Cited by 569
PEGylated antibodies and antibody fragments for improved therapy: a review
Chapman, A. P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00026-1 · Cited by 556
Production of functional chimaeric mouse/human antibody
Boulianne, G. L., Hozumi, N., & Shulman, M. J. (1984) · Nature · doi:10.1038/312643a0 · Cited by 550
From the bench to the bedside: ways to improve rituximab efficacy
Cartron, G., Watier, H., Golay, J., & Solal-Celigny, P. (2004) · Blood · doi:10.1182/blood-2004-03-1110 · Cited by 523
Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins
Dennis, M. S., Zhang, M., Meng, Y. G., Kadkhodayan, M., Kirchhofer, D., Combs, D., & Damico, L. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205854200 · Cited by 508
Ma, J. K.-C., Hikmat, B. Y., Wycoff, K., Vine, N. D., Chargelegue, D., Yu, L., Hein, M. B., & Lehner, T. (1998) · Nature Medicine · doi:10.1038/nm0598-601 · Cited by 505
Ober, R. J., Radu, C. G., Ghetie, V., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.12.1551 · Cited by 501
Austin, C. D., De Mazière, A. M., Pisacane, P. I., van Dijk, S. M., Eigenbrot, C., Sliwkowski, M. X., Klumperman, J., & Scheller, R. H. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-07-0591 · Cited by 496
Human antibodies from transgenic animals.
Lonberg, N. (2005) · Nature Biotechnology · doi:10.1038/nbt1135 · Cited by 434
Optimization of humanized IgGs in glycoengineered Pichia pastoris
Li, H., Sethuraman, N., Stadheim, T. A., Zha, D., Prinz, B., Ballew, N., Bobrowicz, P., Choi, B.-K., Cook, W. J., Cukan, M., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1178 · Cited by 428
Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc
Idusogie, E. E., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Wong, P. Y., Ultsch, M., Meng, Y. G., & Mulkerrin, M. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4178 · Cited by 424
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
Vaccaro, C., Zhou, J., Ober, R. J., & Ward, E. S. (2005) · Nature Biotechnology · doi:10.1038/nbt1143 · Cited by 407
Antigen-specific human antibodies from mice comprising four distinct genetic modifications
Lonberg, N., Taylor, L. D., Harding, F. A., Trounstine, M., Higgins, K. M., Schramm, S. R., Kuo, C.-C., Mashayekh, R., Wymore, K., McCabe, J. G., et al. (1994) · Nature · doi:10.1038/368856a0 · Cited by 398
Schier, R., McCall, A., Adams, G. P., Marshall, K. W., Merritt, H., Yim, M., Crawford, R. S., Weiner, L. M., Marks, C., & Marks, J. D. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0598 · Cited by 382
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
Cragg, M. S., & Glennie, M. J. (2004) · Blood · doi:10.1182/blood-2003-06-2031 · Cited by 360
Green, L. L., Hardy, M. C., Maynard-Currie, C. E., Tsuda, H., Louie, D. M., Mendez, M. J., Abderrahim, H., Noguchi, M., Smith, D. H., Zeng, Y., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-13 · Cited by 355
Therapeutic antibody fragments with prolonged in vivo half-lives
Chapman, A. P., Antoniw, P., Spitali, M., West, S., Stephens, S., & King, D. J. (1999) · Nature Biotechnology · doi:10.1038/11717 · Cited by 350
Reshaping Human Antibodies: Grafting an Antilysozyme Activity
Verhoeyen, M., Milstein, C., & Winter, G. (1988) · Science · doi:10.1126/science.2451287 · Cited by 345
Yang, W.-P., Green, K., Pinz-Sweeney, S., Briones, A. T., Burton, D. R., & Barbas III, C. F. (1995) · Journal of Molecular Biology · doi:10.1006/jmbi.1995.0626 · Cited by 333
Biophysical Properties of Human Antibody Variable Domains
Ewert, S., Huber, T., Honegger, A., & Plückthun, A. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01237-8 · Cited by 330
Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab
Steinman, L. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1752 · Cited by 317
Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn
Ober, R. J., Martinez, C., Vaccaro, C., Zhou, J., & Ward, E. S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2021 · Cited by 314
Fujimori, K., Covell, D. G., Fletcher, J. E., & Weinstein, J. N. (1989) · PubMed · Cited by 299
Antibodies from phage antibody libraries
Bradbury, A. R. M., & Marks, J. D. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.04.007 · Cited by 296
Engineered Antibodies with Increased Activity to Recruit Complement
Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., & Mulkerrin, M. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2571 · Cited by 291
Localization of the binding site for the human high-affinity Fc receptor on IgG
Duncan, A. R., Woof, J. M., Partridge, L. J., Burton, D. R., & Winter, G. (1988) · Nature · doi:10.1038/332563a0 · Cited by 288
Clinical trials of antibody therapy
Glennie, M. J., & Johnson, P. W. M. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01669-8 · Cited by 288
Simmons, L. C., Reilly, D., Klimowski, L., Shantha Raju, T., Meng, G., Sims, P., Hong, K., Shields, R. L., Damico, L. A., Rancatore, P., et al. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(02)00036-4 · Cited by 282
Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates
Hinton, P. R., Johlfs, M. G., Xiong, J. M., Hanestad, K., Ong, K. C., Bullock, C., Keller, S., Tang, M. T., Tso, J. Y., Vásquez, M., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300470200 · Cited by 273
Aggregation-resistant domain antibodies selected on phage by heat denaturation
Jespers, L., Schon, O., Famm, K., & Winter, G. (2004) · Nature Biotechnology · doi:10.1038/nbt1000 · Cited by 266
Antibody humanization: a case of the ‘Emperor’s new clothes’?
Clark, M. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01680-7 · Cited by 258
Exocytosis of IgG as mediated by the receptor, FcRn: An analysis at the single-molecule level
Ober, R. J., Martinez, C., Lai, X., Zhou, J., & Ward, E. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402970101 · Cited by 258
West, A. P., & Bjorkman, P. J. (2000) · Biochemistry · doi:10.1021/bi000749m · Cited by 257
Increasing the serum persistence of an IgG fragment by random mutagenesis
Ghetie, V., Popov, S., Borvak, J., Radu, C., Matesoi, D., Medesan, C., Ober, R. J., & Ward, E. S. (1997) · Nature Biotechnology · doi:10.1038/nbt0797-637 · Cited by 241
Future directions of liposome- and immunoliposome-based cancer therapeutics
Park, J. W., Benz, C. C., & Martin, F. J. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.08.009 · Cited by 240
In Vitro Characterization of Five Humanized OKT3 Effector Function Variant Antibodies
Xu, D., Alegre, M.-L., Varga, S. S., Rothermel, A. L., Collins, A. M., Pulito, V. L., Hanna, L. S., Dolan, K. P., Parren, P. W. H. I., Bluestone, J. A., et al. (2000) · Cellular Immunology · doi:10.1006/cimm.2000.1617 · Cited by 238
Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.
Adams, G. P., Schier, R., Marshall, K., Wolf, E. J., McCall, A. M., Marks, J. D., & Weiner, L. M. (1998) · PubMed · Cited by 230
Niwa, R., Hatanaka, S., Shoji-Hosaka, E., Sakurada, M., Kobayashi, Y., Uehara, A., Yokoi, H., Nakamura, K., & Shitara, K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0850 · Cited by 227
ROSENFELD, P., SCHWARTZ, S., BLUMENKRANZ, M., MILLER, J., HALLER, J., REIMANN, J., GREENE, W., & SHAMS, N. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.01.043 · Cited by 223
Weng, W.-K., & Levy, R. (2001) · Blood · doi:10.1182/blood.v98.5.1352 · Cited by 218
Bolt, S., Routledge, E., Lloyd, I., Chatenoud, L., Pope, H., Gorman, S. D., Clark, M., & Waldmann, H. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230216 · Cited by 218
Choy, E. H. S. (2002) · Rheumatology · doi:10.1093/rheumatology/41.10.1133 · Cited by 213
Drug-conjugated monoclonal antibodies for the treatment of cancer
LAMBERT, J. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.017 · Cited by 210
Farag, S. S., Flinn, I. W., Modali, R., Lehman, T. A., Young, D., & Byrd, J. C. (2004) · Blood · doi:10.1182/blood-2003-07-2548 · Cited by 210
Kenanova, V., Olafsen, T., Crow, D. M., Sundaresan, G., Subbarayan, M., Carter, N. H., Ikle, D. N., Yazaki, P. J., Chatziioannou, A. F., Gambhir, S. S., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.622.65.2 · Cited by 206
Therapeutic antibody expression technology
Chadd, H. E., & Chamow, S. M. (2001) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(00)00198-1 · Cited by 204
Wu, H., Pfarr, D. S., Tang, Y., An, L.-L., Patel, N. K., Watkins, J. D., Huse, W. D., Kiener, P. A., & Young, J. F. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.04.049 · Cited by 204
Willuda, J., Honegger, A., Waibel, R., Schubiger, P. A., Stahel, R. A., Zangemeister‐Wittke, U., & Plückthun, A. (1999) · PubMed · Cited by 200
Selection of tumor-specific internalizing human antibodies from phage libraries
Poul, M.-A., Becerril, B., Nielsen, U. B., Morisson, P., & Marks, J. D. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4026 · Cited by 192
Woodle, E. S., Xu, D., Zivin, R. A., Auger, J., Charette, J., O'Laughlin, R., Peace, D., Jolliffe, L. K., Haverty, T., Bluestone, J. A., et al. (1999) · Transplantation · doi:10.1097/00007890-199909150-00003 · Cited by 188
Minimizing the immunogenicity of protein therapeutics
Chirino, A. J., Ary, M. L., & Marshall, S. A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02953-2 · Cited by 177
Alegre, M.-L., Peterson, L. J., Xu, D., Sattar, H. A., Jeyarajah, D. R., Kowalkowski, K., Thistlethwaite, J. R., Zivin, R. A., Jolliffe, L., & Bluestone, J. A. (1994) · Transplantation · doi:10.1097/00007890-199457110-00001 · Cited by 171
Transcytosis and Catabolism of Antibody
Ghetie, V. F., & Ward, E. S. (2002) · Immunologic Research · doi:10.1385/ir:25:2:097 · Cited by 163
Ten Years of Orthoclone OKT3 (Muromonab-CD3): A Review
Smith, S. L. (1996) · Journal of Transplant Coordination · doi:10.1177/090591999600600304 · Cited by 163
Persic, L., Roberts, A., Wilton, J., Cattaneo, A., Bradbury, A., & Hoogenboom, H. R. (1997) · Gene · doi:10.1016/s0378-1119(96)00628-2 · Cited by 162
Renaissance of cancer therapeutic antibodies
Glennie, M. J., & van de Winkel, J. G. J. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02714-4 · Cited by 155
Werther, W., González, T., O'Connor, S. L., McCabe, S., Chan, B., Hotaling, T. E., Champe, M., Fox, J. A., Jardieu, P. M., Berman, P. W., et al. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.11.4986 · Cited by 148
Immunogenicity of therapeutic monoclonal antibodies.
Pendley, C. E., Schantz, A., & Wagner, C. (2003) · PubMed · Cited by 147
Identification and validation of cell surface antigens for antibody targeting in oncology
Carter, P. M., Smith, L. M., & Ryan, M. C. (2004) · Endocrine Related Cancer · doi:10.1677/erc.1.00766 · Cited by 145
Self-citationPHASE I STUDY OF AN ENGINEERED AGLYCOSYLATED HUMANIZED CD3 ANTIBODY IN RENAL TRANSPLANT REJECTION1
Friend, P. J., Hale, G., Chatenoud, L., Rebello, P., Bradley, J. R., Thiru, S. S., Phillips, J. M., & Waldmann, H. (1999) · Transplantation · doi:10.1097/00007890-199912150-00005 · Cited by 145
Molecular Evolution of Antibody Affinity for Sensitive Detection of Botulinum Neurotoxin Type A
Razai, A., Garcia-Rodriguez, C., Lou, J., Geren, I. N., Forsyth, C. M., Robles, Y., Tsai, R. M., Smith, T. J., Smith, L. A., Siegel, R. W., et al. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.06.003 · Cited by 142
Babcook, J. S., Leslie, K. B., Olsen, O. A., Salmon, R. A., & Schrader, J. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7843 · Cited by 132
Efficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates
Law, C., Cerveny, C. G., Gordon, K. A., Klussman, K., Mixan, B. J., Chace, D. F., Meyer, D. L., Doronina, S. O., Siegall, C. B., Francisco, J. A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1028 · Cited by 116
Edwards, B. M., Barash, S. C., Main, S. H., Choi, G. H., Minter, R., Ullrich, S. J., Williams, E. M., Fou, L. D., Wilton, J., Albert, V. R., et al. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.09.054 · Cited by 111
Nielsen, U. B., Adams, G. P., Weiner, L. M., et al. (2000) · PubMed · Cited by 110
Mejías, A., Chávez‐Bueno, S., Ríos, A. M., Fonseca-Aten, M., Raynor, B., Peromingo, E., Soni, P., Olsen, K. D., Kiener, P. A., Gomez-Lahoz, A. M., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4700-4707.2005 · Cited by 107
Schlereth, B., Quadt, C., Dreier, T., Kufer, P., Lorenczewski, G., Prang, N., Brandl, C., Lippold, S., Cobb, K., Brasky, K., et al. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0001-1 · Cited by 103
Engineering Antibodies for Therapy
Presta, L. G. (2002) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023378256 · Cited by 94
Liu, B., Conrad, F., Cooperberg, M. R., Kirpotin, D. B., & Marks, J. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2732 · Cited by 93
Depletion of B Cells by a Humanized Anti-CD20 Antibody PRO70769 in Macaca Fascicularis
Vugmeyster, Y., Beyer, J. C., Howell, K., Combs, D., Fielder, P. J., Yang, J., Qureshi, F., Sandlund, B., Kawaguchi, L., Dummer, W., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000155050.03916.04 · Cited by 79
Retargeting serum immunoglobulin with bispecific diabodies
Holliger, P., Wing, M. G., Pound, J. D., Bohlen, H., & Winter, G. P. (1997) · Nature Biotechnology · doi:10.1038/nbt0797-632 · Cited by 79
Generation and Production of Engineered Antibodies
Kipriyanov, S. M., & Gall, F. L. (2004) · Molecular Biotechnology · doi:10.1385/mb:26:1:39 · Cited by 76
Mayer, A., Tsiompanou, E., O'Malley, D., Boxer, G., Bhatia, J., Flynn, A. A., Chester, K. A., Davidson, B. R., Lewis, A. A. M., Winslet, M. C., et al. (2000) · PubMed · Cited by 75
Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells
Cole, M. S., Anasetti, C., & Tso, J. Y. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.7.3613 · Cited by 73
Flexibility—the guiding principle for antibody manufacturing
Carson, K. L. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1054 · Cited by 71
Norman, D. J., Vincenti, F. G., de Mattos, A. M., et al. (2000) · Transplantation · doi:10.1097/00007890-200012270-00008 · Cited by 70
Tailor-made antibody therapeutics
Chowdhury, P. S., & Wu, H. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.002 · Cited by 67
Intrabodies as therapeutic agents
Kontermann, R. E. (2004) · Methods · doi:10.1016/j.ymeth.2004.04.002 · Cited by 58
Targeting Weak Antigens to CD64 Elicits Potent Humoral Responses in Human CD64 Transgenic Mice
Keler, T., Guyre, P. M., Vitale, L. A., Sundarapandiyan, K., van de Winkel, J. G. J., Deo, Y. M., & Graziano, R. F. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.6738 · Cited by 57
Kimball, J. A., Norman, D. J., Shield, C. F., Schroeder, T., Lisi, P. J., Garovoy, M. R., O'Connell, J. B., Stuart, F. P., McDiarmid, S. V., & Wall, W. J. (1995) · Transplant Immunology · doi:10.1016/0966-3274(95)80027-1 · Cited by 55
Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6.
Brooks, D., Taylor, C. G., Santos, B. D., Linden, H. C. D. V., Houghton, A., Hecht, T. T., Kornfeld, S. A., & Taetle, R. (1995) · PubMed · Cited by 55
Redesigning an Antibody Fragment for Faster Association with Its Antigen
Marvin, J. S., & Lowman, H. B. (2003) · Biochemistry · doi:10.1021/bi026947q · Cited by 52
Minimizing the Immunogenicity of Antibodies for Clinical Application
Gonzales, N. R., Pascalis, R. D., Schlom, J., & Kashmiri, S. V. S. (2005) · Tumor Biology · doi:10.1159/000084184 · Cited by 51
Integrating cell-level kinetic modeling into the design of engineered protein therapeutics
Rao, B. M., Lauffenburger, D. A., & Wittrup, K. D. (2005) · Nature Biotechnology · doi:10.1038/nbt1064 · Cited by 50
In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.
Parlevliet, K. J., ten Berge, I. J. M., Yong, S. L., Surachno, J. S., Wilmink, J. M., & Schellekens, P. T. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117262 · Cited by 47
Creating the next generation of protein therapeutics through rational drug design.
Szymkowski, D. E. (2005) · PubMed · Cited by 40
Intrabodies: production and promise
Stocks, M. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03269-6 · Cited by 36
Nature's best weapons to fight cancer. Revival of human monoclonal IgM antibodies
Vollmers, H. P., & Brändlein, S. (2003) · Human Antibodies · doi:10.3233/hab-2002-11403 · Cited by 34
Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation
Chatenoud, L. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.03.012 · Cited by 26
Scott, C. T. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1037 · Cited by 25
Cited by
Interfering with pH regulation in tumours as a therapeutic strategy
Neri, D., & Supuran, C. T. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3554 · Cited by 1,547
Ultrahigh-throughput screening in drop-based microfluidics for directed evolution
Agresti, J. J., Antipov, E., Abate, A. R., Ahn, K., Rowat, A. C., Baret, J.-C., Marquez, M., Klibanov, A. M., Griffiths, A. D., & Weitz, D. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910781107 · Cited by 1,149
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Droplet microfluidics for high-throughput biological assays
Guo, M. T., Rotem, A., Heyman, J. A., & Weitz, D. A. (2012) · Lab on a Chip · doi:10.1039/c2lc21147e · Cited by 1,040
Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence
Chinen, A. B., Guan, C. M., Ferrer, J. R., Barnaby, S. N., Merkel, T. J., & Mirkin, C. A. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00321 · Cited by 1,032
Metadata
- Authors
- Carter, P. J.
- Venue
- Nature Reviews Immunology
- Published
- 2006-04-07
- Volume
- 6
- Issue
- 5
- Pages
- 343-357
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2050754173
- Cited by
- 1,099
- References
- 128
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.